Last reviewed · How we verify
NYPOZI (FILGRASTIM-TXID)
NYPOZI (generic name: FILGRASTIM-TXID) is a Leukocyte Growth Factor [EPC] drug developed by TANVEX BIOPHARMA USA INC. It is currently FDA-approved for Febrile Neutropenia in Nonmyeloid Malignancies, Neutrophil Recovery in AML, Neutropenia in BMT.
G-CSF binds to specific receptors on hematopoietic cells, stimulating neutrophil production and function.
At a glance
| Generic name | FILGRASTIM-TXID |
|---|---|
| Sponsor | TANVEX BIOPHARMA USA INC |
| Drug class | Leukocyte Growth Factor [EPC] |
| Target | Specific cell surface receptors on hematopoietic cells |
| Therapeutic area | Other |
| Phase | FDA-approved |
Mechanism of action
G-CSF is a glycoprotein that acts on hematopoietic cells by binding to specific receptors. This binding stimulates the proliferation, differentiation, and functional activation of neutrophils, enhancing their phagocytic ability and other functions.
Approved indications
- Febrile Neutropenia in Nonmyeloid Malignancies
- Neutrophil Recovery in AML
- Neutropenia in BMT
- Progenitor Cell Mobilization
- Severe Chronic Neutropenia
- Radiation Exposure
Common side effects
- Thrombocytopenia
- Nausea
- Pyrexia
- Chest pain
- Pain
- Fatigue
- Back pain
- Arthralgia
- Bone pain
- Pain in extremity
- Dizziness
- Cough
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NYPOZI CI brief — competitive landscape report
- NYPOZI updates RSS · CI watch RSS
- TANVEX BIOPHARMA USA INC portfolio CI
Frequently asked questions about NYPOZI
What is NYPOZI?
How does NYPOZI work?
What is NYPOZI used for?
Who makes NYPOZI?
What is the generic name of NYPOZI?
What drug class is NYPOZI in?
What development phase is NYPOZI in?
What are the side effects of NYPOZI?
What does NYPOZI target?
Related
- Drug class: All Leukocyte Growth Factor [EPC] drugs
- Target: All drugs targeting Specific cell surface receptors on hematopoietic cells
- Manufacturer: TANVEX BIOPHARMA USA INC — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Febrile Neutropenia in Nonmyeloid Malignancies
- Indication: Drugs for Neutrophil Recovery in AML
- Indication: Drugs for Neutropenia in BMT
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing